Effectiveness of Tranexamic Acid in Trauma Patients: A Systematic Review

Abstract

Tranexamic acid (TXA), a fibrinolytic agent, effectively inhibits plasminogen activation, thereby reducing fibrinolysis and hemorrhage. This study focused on its application in trauma patients undergoing emergency surgery, a critical area due to trauma's significant role in mortality. Our investigation involved a meticulous screening of randomized controlled trials from databases including Scopus, PubMed, Web of Science, and Cochrane. The findings indicate that TXA intervention is promising in enhancing outcomes for trauma patients. However, the drug's effectiveness may vary based on the specific nature of the medical condition. In summary, robust evidence suggests that TXA can diminish blood loss, lower transfusion rates, reduce complications, and improve hemoglobin and hematocrit levels in surgical patients. Consequently, TXA should be considered a crucial medication, readily available to mitigate morbidity and mortality in surgical settings. Future research should explore factors influencing TXA's effectiveness in traumatic brain injury cases and across a broad spectrum of surgical scenarios in diverse patient populations. This would further guide clinicians in refining and optimizing the use of TXA.

The Prediction and Treatment of Bleeding Esophageal Varices in the Artificial Intelligence Era: A Review

“…Tranexamic acid binds a lysine receptor in plasmin and inhibits fibrinolysis. A recent systematic review demonstrated how the early management of tranexamic acid has been shown to have positive outcomes in gastrointestinal bleeding and traumatic events; it reduces continued gastrointestinal bleeding and urgent endoscopic intervention but has not shown improvement in all causes of mortality [44,57,58].…”